Visual deficit possibly caused by lutetium-177 PSMA treatment

Ludwike van Kalmthout; Anine Stam; Renze Gans; Marnix Lam

doi:10.1136/bcr-2018-225508

Visual deficit possibly caused by lutetium-177 PSMA treatment

Ludwike van Kalmthout
, Anine Stam
, Renze Gans
, Marnix Lam

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy. Describing this case, we aim to add to the discussion on 177Lu-PSMA safety, in which prospective research will ultimately offer definite answers.

Original language	English
Article number	225508
Number of pages	4
Journal	BMJ Case Reports [E]
Volume	2018
DOIs	https://doi.org/10.1136/bcr-2018-225508
Publication status	Published - 2018

Keywords

prostate cancer
unwanted effects / adverse reactions

Access to Document

10.1136/bcr-2018-225508

kalmthoutFinal published version, 705 KBLicence: Taverne

Cite this

@article{d1b9ae4a973449c7b148811b1ef4b5f2,

title = "Visual deficit possibly caused by lutetium-177 PSMA treatment",

abstract = "This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy. Describing this case, we aim to add to the discussion on 177Lu-PSMA safety, in which prospective research will ultimately offer definite answers.",

keywords = "prostate cancer, unwanted effects / adverse reactions",

author = "\{van Kalmthout\}, Ludwike and Anine Stam and Renze Gans and Marnix Lam",

note = "Publisher Copyright: {\textcopyright} BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2018",

doi = "10.1136/bcr-2018-225508",

language = "English",

volume = "2018",

journal = "BMJ Case Reports [E]",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Visual deficit possibly caused by lutetium-177 PSMA treatment

AU - van Kalmthout, Ludwike

AU - Stam, Anine

AU - Gans, Renze

AU - Lam, Marnix

N1 - Publisher Copyright: © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2018

Y1 - 2018

N2 - This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy. Describing this case, we aim to add to the discussion on 177Lu-PSMA safety, in which prospective research will ultimately offer definite answers.

AB - This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy. Describing this case, we aim to add to the discussion on 177Lu-PSMA safety, in which prospective research will ultimately offer definite answers.

KW - prostate cancer

KW - unwanted effects / adverse reactions

UR - https://www.scopus.com/pages/publications/85054709177

U2 - 10.1136/bcr-2018-225508

DO - 10.1136/bcr-2018-225508

M3 - Article

C2 - 30301726

SN - 1757-790X

VL - 2018

JO - BMJ Case Reports [E]

JF - BMJ Case Reports [E]

M1 - 225508

ER -

Visual deficit possibly caused by lutetium-177 PSMA treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this